CAP-1002

CAP-1002

Status

Phase ||

Therapeutic Approach

Improving Muscle Growth & Protection

CAP-1002 is a cell therapy. It is an allogeneic product, meaning it is manufactured from donor heart tissue and then stored until needed for use. CAP-1002 consists of allogeneic cardiosphere-derived cells, a unique population of cells that contains cardiac progenitor cells. It is thought to decrease inflammation and muscle degeneration while exerting positive effects on muscle regeneration, all of which may translate into patients retaining muscle function for a longer period of time.

Status

A Phase 2 clinical trial to evaluate the safety and efficacy of repeat doses of CAP-1002 in boys and young men with Duchenne muscular dystrophy and reduced upper limb function is ongoing.

Sponsor

This program is sponsored by Capricor Therapeutics.

Related Studies

ONGOING
HOPE-2 A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients

Media Library

JUNE 2020

Webinar: Capricor's HOPE-2 Final 12-Month Data


On June 3, 2020, Capricor joined Parent Project Muscular Dystrophy for a webinar to discuss Capricor’s HOPE-2 clinical program, following the company’s announcement of positive final 12-month results from the HOPE-2 Trial.
JULY 2019

Webinar: Capricor’s HOPE-2 Interim Analysis


On July 17, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE-2 clinical program, following the company’s announcement of positive results from their interim analysis in the HOPE-2 Trial after placing a voluntary dosing hold earlier in the year.
APRIL 2019

Webinar: Capricor’s Clinical Program


On April 24, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE2 clinical program.
JULY 2018

Webinar: HOPE-2 Duchenne Clinical Trial – Capricor

PPMD and Capricor hosted a webinar on July 18, 2018 to discuss the HOPE-2 trial. Capricor provided a brief background of CAP-1002 and its clinical development to date that has led to this exciting trial. The webinar also reviewed the trial design, eligibility criteria, and assessments that participants will need to complete if they participate in the trial, as well as the travel policy for participants who need to travel to a trial site.
JUNE 2018

Capricor Presents at the PPMD 2018 Annual Conference

NOV 2017

Webinar: Capricor Therapeutics' HOPE-Duchenne Clinical Trial

Capricor Therapeutics joined PPMD for a webinar on November 30, 2017 to discuss the 12-month results from Capricor's HOPE-Duchenne Clinical Trial, as well as the company’s plans for the HOPE-2 Clinical Trial in the first quarter of 2018, pending regulatory approval.
APRIL 2017

Webinar: Capricor Therapeutics' HOPE-Duchenne Clinical Trial

Parent Project Muscular Dystrophy, Coalition Duchenne, and Capricor hosted a webinar on April 28, 2017 to hear a community update on the six-month results from Capricor's randomized Phase I/II HOPE Clinical Trial of CAP-1002 (allogeneic cardiosphere-derived cells), an investigational candidate for the treatment of Duchenne.

Join Our Mailing List